Target intelligence / Profile preview

Myopic defocus

Molecular classification
Other (physical stimulus, not a molecule or receptor)
01

Overview

"Myopic defocus" refers to a retinal image condition where light rays are focused in front of the retina, causing distance vision to be blurred. It can be induced experimentally or therapeutically (e.g., with positive lenses) to trigger a cascade of retinal signaling pathways that suppress ocular axial elongation, thereby slowing the progression of myopia. It is a critical concept in understanding the feedback control of postnatal eye growth (emmetropization) and is the basis for optical strategies to prevent or reduce the worsening of nearsightedness. However, it is not itself a molecule, receptor, or direct therapeutic target, but an optical/biophysical phenomenon that influences biological processes through the retina.

Other names
Positive optical defocusPositive lens-induced defocus (in experimental contexts)Retinal myopic defocus (context-dependent)
02

Mechanism of action

Inducing "myopic defocus" (i.e., presenting a blurred image where the light focuses in front of the retina, such as with positive lens wear) suppresses axial eye growth through retinal signaling pathways that ultimately decrease myopia progression.

03

Biological functions

Regulation of axial eye growthSuppression of excessive eye elongationSignal in emmetropization (process by which the eye grows to achieve focused vision)
04

Disease associations

Other: Used in experimental and clinical settings for the control of myopia progression (not a pathogenic factor but a therapeutic input)
05

Safety considerations

As an optical intervention (used in myopia management devices): minimal risk but may cause transient blurred distance vision, visual discomfort, or reduced visual acuity at certain distances. No molecular safety profile exists
06

Interacting drugs

None directly; however, drugs such as atropine can modulate molecular pathways also affected by optical defocus, but not by interacting with "myopic defocus" as such
07

Biomarkers

Gene expression changes in the retina (e.g., RANK, Notch, JAK/Stat pathways), but no canonical molecular biomarker for "myopic defocus" itself

Beyond the preview

Go deeper on Myopic defocus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myopic defocus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call